<DOC>
	<DOCNO>NCT02981979</DOCNO>
	<brief_summary>The purpose study investigate efficacy Safety Leflunomide Patients With Active Phase Takayasu 's Arteritis</brief_summary>
	<brief_title>Takayasu Arteritis Clinical Trial China</brief_title>
	<detailed_description />
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Takayasu Arteritis</mesh_term>
	<mesh_term>Aortic Arch Syndromes</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>1 . Signed informed consent form ; 2 . Subjects meet American College Rheumatology 1990 classification criterion Takayasu arteritis : 2.1 Age onset ≤40 year ; 2.2 Claudication upper low extremity ; 2.3 Decreased pulsation 1 brachial artery ; 2.4 Difference ≥ 10 mmHg systolic blood pressure arm ; 2.5 Bruit subclavian artery aorta ; 2.6 Angiography * show branch aorta stenosis occlusion ; Meeting 3 6 criterion suggest diagnosis Takayasu arteritis . * Angiography study replace vascular magnetic resonance angiography（MRA）or compute tomography angiography（CTA） . 3 . Males female age 18 65 year ; 4 . All subject agree childbearing plan clinical trial , result serum urine pregnancy test female must negative ; 5 . Evidence disease active phase past 3 month , meet least 2 follow criterion : 5.1 There new onset vascular ischemia , accordance least one following : 5.1.1 newly discover difference blood pressure arm ( systolic pulse pressure difference least ≥ 10mmHg ) ; 5.1.2 new onset decrease pulsation 1 brachial artery ; 5.1.3 new manifestation vascular ischemia ; 5.2 Inflammatory abnormality , meet least one following : 5.2.1 Erythrocyte sedimentation rate（ESR） level high normal upper limit（others factor like infection excluded） ; 5.2.2 highsensitivity Creactive protein（hsCRP）≥ 6mg/L Creactive protein（CRP） &gt; 10mg/L ; 5.3 Imaging examination show abnormalities suggest disease active phase , meet least one following : 5.3.1 Vascular wall show enhance signal MRA ( active inflammation ) ; 5.3.2 enhance CTA suggest new vascular lesion ; 5.3.3 Color Doppler ultrasonography suggest vascular wall inflammation ; 5.4 Systemic symptom explain cause : fever , fatigue lose weight . 1 . Takayasu arteritis show lesion vascular dilatation aneurysm formation ; 2 . Takayasu arteritis patient undergone surgical procedure , example , heart valve replacement renal artery stenting ; 3 . Subjects organ failure , meeting least one following : 3.1 Cardiac function : New York Heart Association grade 4 ; 3.2 Glomerular filtration rate ≤ 60ml/min ; 3.3 Liver function： Childpugh grade 2 bad grade 2 ; 3.4 High frequency amaurosis ( flare 3 consecutive day ) ; 3.5 Acute cerebral infarction cerebral hemorrhage ; 3.6 Blood pressure &gt; 160/100mmHg ; 4 . Suffer autoimmune disease ( eg , ANCAassociated vasculitis , systemic lupus erythematosus , Behcet 's disease , etc . ) besides Takayasu arteritis ; 5 . Serious progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurological , coexist medical condition associate Takayasu 's artery may result unacceptable risk ; 6 . Comorbidities asthma may require use medium high dos glucocorticoid ( prednisone ≥ 10 mg/day equivalent dos prednisone equivalent ) study period ; 7. subject history malignancy diseases ; 8 . Subjects serious acute chronic infection ; 9 . Hepatitis B surface antigen positive hepatitis B DNA positive ; 10 . Hepatitis C RNA positive ; 11 . Subjects risk tuberculosis , especially follow condition : 11.1 clinical radiological laboratory evidence active occult tuberculosis ; 11.2 History active tuberculosis , even treat ; 12 . Subjects abnormal laboratory test result , meet least 1 follow : 12.1 Subjects serum alanine aminotransferase ( ALT ) glutamicoxalacetic transaminase（AST）≥1.5 fold normal upper limit ; 12.2 Blood white blood cell count ≤4×10^9 / L ; 12.3 Platelet count ≤100 × 10^9 / L ; 12.4 Hemoglobin ≤100g / L ; 12.5 Other laboratory test abnormality may contribute unacceptable risk participant study ; 13 . Subjects allergic investigational drug ; 14 . Use treatment and/or medication allow trial : 14.1 History leflunomide treatment least 3 month effective ; 14.2 Subjects receive cyclophosphamide leflunomide last 6 month ; 14.3 last 3 month , use azathioprine , methotrexate , mycophenolate mofetil , cyclosporine , tacrolimus , thalidomide , antimalarial , treatment Takayasu arteritis , specially permit protocol ; 14.4 Use traditional Chinese medicine proprietary Chinese medicine last 3 month ; 14.5 Received biological agent rituximab , interleukin（IL）6 receptor antagonist , tumor necrosis factor inhibitor last 6 month ; 14.6 Subjects undergone plasmapheresis lymphocyte replacement immunosorbent therapy last one year , plan receive treatment ; 14.7 Patients willing receive attenuate vaccine trial ; 14.8 Subjects accept plan organ transplantation ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Takayasu Arteritis</keyword>
	<keyword>Leflunomide</keyword>
</DOC>